Author:
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 25 | 25 | 8 |
| Full Text Views | 404 | 131 | 1 |
| PDF Downloads | 119 | 36 | 0 |
Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria.
E C Duarte
E C Duarte
National Health Foundation, Ministry of Health, Brazil. eduarte@zaz.com.br
Search for other papers by E C Duarte in
Current site
Google Scholar
PubMed
Search for other papers by E C Duarte in
Current site
Google Scholar
PubMed
L W Pang
L W Pang
National Health Foundation, Ministry of Health, Brazil. eduarte@zaz.com.br
Search for other papers by L W Pang in
Current site
Google Scholar
PubMed
Search for other papers by L W Pang in
Current site
Google Scholar
PubMed
L C Ribeiro
L C Ribeiro
National Health Foundation, Ministry of Health, Brazil. eduarte@zaz.com.br
Search for other papers by L C Ribeiro in
Current site
Google Scholar
PubMed
Search for other papers by L C Ribeiro in
Current site
Google Scholar
PubMed
C J Fontes
C J Fontes
National Health Foundation, Ministry of Health, Brazil. eduarte@zaz.com.br
Search for other papers by C J Fontes in
Current site
Google Scholar
PubMed
Search for other papers by C J Fontes in
Current site
Google Scholar
PubMed
This study evaluated the cure rate of the standard recommended regimen for Plasmodium vivax malaria in Brazil and assessed risk factors for failures. Fifty patients with vivax malaria given supervised medical treatment (standard dose of chloroquine: total dose = 1.5 g over a three-day period plus primaquine: total dose = 210 mg over a 14-day period) were followed for six months in a non-endemic area. Cox's regression was used to identify predictors of relapses. Among the 289 patient-months of follow-up, seven relapses were identified (2.4 relapses per 100 person-months) between 33 and 137 days after treatment initiation. Risk factors for relapses (P < or = 0.05) were female sex, higher parasitemia at baseline, shorter number of days with symptoms prior to baseline, and lower mg/kg dose of primaquine. Relapses following supervised vivax treatment is in principle a necessary, but not sufficient, component of in vivo parasite resistance. Results indicate that other factors, principally sub-therapeutic primaquine doses, may explain the occurrence of vivax treatment failures.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 25 | 25 | 8 |
| Full Text Views | 404 | 131 | 1 |
| PDF Downloads | 119 | 36 | 0 |